Atypische Parkinsonsyndrome – Neues aus Diagnostik und Therapie

P. Fuchs; G. K. Wenning

doi:10.1055/s-0032-1331773

Aktuelle Neurologie, Inhaltsverzeichnis

Aktuelle Neurologie 2012; 39(10): 534-545
DOI: 10.1055/s-0032-1331773

Übersicht

Atypische Parkinsonsyndrome – Neues aus Diagnostik und Therapie

Atypical Parkinsonian Disorders – New Aspects in Diagnosis and Therapy

P. Fuchs

¹Universitätsklinik für Neurologie, Medizinische Universität Innsbruck, Österreich

,

G. K. Wenning

¹Universitätsklinik für Neurologie, Medizinische Universität Innsbruck, Österreich

› Institutsangaben

Abstract

Zusammenfassung

Die meisten Patienten mit Parkinsonismus leiden an einem idiopathischen Parkinsonsyndrom (idiopathic Parkinson`s disease=IPD), doch präsentiert sich eine beträchtliche Minderzahl mit zusätzlichen atypischen Symptomen. Diese als atypische Parkinsonsyndrome (atypical parkinsonian disorders=APDs) bezeichneten Erkrankungen, können (differenzial-) diagnostische Schwierigkeiten bereiten. Allen APDs gemeinsam sind die rasche Progression und der häufig schlecht oder gar nicht auf Levodopa ansprechende Parkinsonismus. Neben der Multisystematrophie (MSA) und der Demenz mit Lewy-Körperchen (Dementia with Lewy bodies=DLB), die zusammen mit dem IPD zu den α-Synucleinopathien gezählt werden, werden die progressive supranukleäre Blickparese (PSP) und kortikobasale Degeneration (CBD; beides Tauopathien) dem Komplex der APDs zugeordnet. In den letzten Jahrzehnten lieferten eine Fülle von wissenschaftlichen Studien zahlreiche neue Erkenntnisse und steigerten damit auch das Bewusstsein für die APDs in der Klinik. Durch die Anwendung moderner Untersuchungsverfahren in Kombination mit internationalen Diagnosekriterien kann verlässlicher denn je die Diagnose eines APD gestellt werden.

Dieser Artikel gibt einen Überblick über die aktuellen Entwicklungen in den Bereichen Diagnostik und Therapie auf dem Gebiet der APDs.

Abstract

Most patients presenting with parkinsonism suffer from idiopathic Parkinson’s disease (IPD). However some patients develop additional atypical features that can cause problems in the differential diagnosis. The atypical parkinsonian disorders (APDs) include synucleinopathies such as multiple system atrophy (MSA) and dementia with Lewy bodies (DLB), as well as progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) which belong to the tauopathies. All APDs share a rapid progression and a poor or absent response to Levodopa treatment. In the past few years new scientific approaches increased the knowledge about these syndromes dramatically and with it also the awareness of the clinicians. Improved international diagnostic criteria and advances in neuroimaging have significantly facilitated the diagnosis of this group of diseases.

This article provides a comprehensive summary of novel developments in the diagnostic and therapeutic fields of APDs.

Schlüsselwörter

atypischer Parkinsonismus - Multisystematrophie - progressive supranukleäre Blickparese - Lewy-Körperchen Demenz - kortikobasale Degeneration

Keywords

atypical Parkinsonism - multiple system atrophy - progressive supranuclear palsy - dementia with Lewy bodies - corticobasal degeneration

Volltext

Referenzen

Literatur
1 Wenning GK, Litvan I, Tolosa E. Milestones in atypical and secondary Parkinsonisms. Mov Disord 2011; 26: 1083-1095
2 Wenning GK, Krismer F, Poewe W. New insights into atypical parkinsonism. Curr Opin Neurol 2011; 24: 331-338
3 Horvath J, Burkhard PR, Bouras C et al. Etiologies of Parkinsonism in a Century-Long Autopsy-Based Cohort. Brain Pathol 2012;
4 Kollensperger M, Geser F, Ndayisaba JP et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 2010; 25: 2604-2612
5 Vanacore N, Bonifati V, Fabbrini G et al. Epidemiology of multiple system atrophy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. Neurol Sci 2001; 22: 97-99
6 Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999; 354: 1771-1775
7 Spillantini MG, Crowther RA, Jakes R et al. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neurosci Lett 1998; 251: 205-208
8 Wenning GK, Stefanova N, Jellinger KA et al. Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol 2008; 64: 239-246
9 Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989; 94: 79-100
10 Wenning GK, Tison F, Seppi K et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord 2004; 19: 1391-1402
11 Gilman S, Low PA, Quinn N et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999; 163: 94-98
12 Gilman S, Wenning GK, Low PA et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670-676
13 Stefanova N, Reindl M, Neumann M et al. Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. Mov Disord 2007; 22: 2196-2203
14 Stefanova N, Reindl M, Neumann M et al. Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol 2005; 166: 869-876
15 Shults CW, Rockenstein E, Crews L et al. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J Neurosci 2005; 25: 10689-10699
16 Yazawa I, Giasson BI, Sasaki R et al. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 2005; 45: 847-859
17 Stefanova N, Tison F, Reindl M et al. Animal models of multiple system atrophy. Trends Neurosci 2005; 28: 501-506
18 Stefanova N, Bucke P, Duerr S et al. Multiple system atrophy: an update. Lancet Neurol 2009; 8: 1172-1178
19 Schrag A, Good CD, Miszkiel K et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000; 54: 697-702
20 Massey LA, Micallef C, Paviour DC et al. Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord 2012;
21 Kimpinski K, Iodice V, Burton DD et al. The role of autonomic testing in the differentiation of Parkinson’s disease from multiple system atrophy. J Neurol Sci 2012; 317: 92-96
22 Tha KK, Terae S, Yabe I et al. Microstructural white matter abnormalities of multiple system atrophy: in vivo topographic illustration by using diffusion-tensor MR imaging. Radiology 2010; 255: 563-569
23 Minnerop M, Luders E, Specht K et al. Callosal tissue loss in multiple system atrophy – a one-year follow-up study. Mov Disord 2010; 25: 2613-2620
24 Brooks DJ, Seppi K. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord 2009; 24: 949-964
25 Hellwig S, Amtage F, Kreft A et al. [18F]FDG-PET is superior to [123I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 2012; 79: 1314-1322
26 Kikuchi A, Takeda A, Okamura N et al. In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain 2010; 133: 1772-1778
27 Hong Z, Shi M, Chung KA et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain 2010; 133: 713-726
28 Tokuda T, Salem SA, Allsop D et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. Biochem Biophys Res Commun 2006; 349: 162-166
29 Constantinescu R, Andreasson U, Li S et al. Proteomic profiling of cerebrospinal fluid in parkinsonian disorders. Parkinsonism Relat Disord 2010; 16: 545-549
30 Ishigami N, Tokuda T, Ikegawa M et al. Cerebrospinal fluid proteomic patterns discriminate Parkinson’s disease and multiple system atrophy. Mov Disord 2012; 27: 851-857
31 Brown RG, Lacomblez L, Landwehrmeyer BG et al. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 2010; 133: 2382-2393
32 Wenning GK, Colosimo C, Geser F et al. Multiple system atrophy. Lancet Neurol 2004; 3: 93-103
33 Flabeau O, Meissner WG, Tison F. Multiple system atrophy: current and future approaches to management. Ther Adv Neurol Disord 2010; 3: 249-263
34 Wenning GK, Ben Shlomo Y, Magalhaes M et al. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994; 117 (Pt 4) 835-845
35 Jain S, Dawson J, Quinn NP et al. Occupational therapy in multiple system atrophy: a pilot randomized controlled trial. Mov Disord 2004; 19: 1360-1364
36 Park HJ, Bang G, Lee BR et al. Neuroprotective effect of human mesenchymal stem cells in an animal model of double toxin-induced multiple system atrophy parkinsonism. Cell Transplant 2011; 20: 827-835
37 Holmberg B, Johansson JO, Poewe W et al. Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study. Mov Disord 2007; 22: 1138-1144
38 Bensimon G, Ludolph A, Agid Y et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 2009; 132: 156-171
39 Dodel R, Spottke A, Gerhard A et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 2010; 25: 97-107
40 Poewe W, Barone P, Gliadi N et al. A randomized, placebo-controlled clinical trial to assess the effects of rasagiline in patients with multiple system atrophy of the parkinsonian subtype [abstract]. Mov Disord 2012; 27
41 Novak P, Williams A, Ravin P et al. Treatment of multiple system atrophy using intravenous immunoglobulin. BMC Neurol 2012; 12: 131
42 Sacca F, Marsili A, Quarantelli M et al. A randomized clinical trial of lithium in multiple system atrophy. J Neurol 2012;
43 Kollensperger M, Krismer F, Pallua A et al. Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy. Mov Disord 2011; 26: 507-515
44 Lee PH, Lee JE, Kim HS et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol 2012; 72: 32-40
45 McKeith I. Dementia with Lewy bodies. Dialogues Clin Neurosci 2004; 6: 333-341
46 Matsui Y, Tanizaki Y, Arima H et al. Incidence and survival of dementia in a general population of Japanese elderly: the Hisayama study. J Neurol Neurosurg Psychiatry 2009; 80: 366-370
47 Rahkonen T, Eloniemi-Sulkava U, Rissanen S et al. Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. J Neurol Neurosurg Psychiatry 2003; 74: 720-724
48 McKeith IG, Dickson DW, Lowe J et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872
49 Weintraub D, Hurtig HI. Presentation and management of psychosis in Parkinson’s disease and dementia with Lewy bodies. Am J Psychiatry 2007; 164: 1491-1498
50 McKeith IG, Galasko D, Kosaka K et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113-1124
51 Schulz-Schaeffer WJ. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta Neuropathol 2010; 120: 131-143
52 Perry RH, Irving D, Blessed G et al. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990; 95: 119-139
53 Hansen L, Salmon D, Galasko D et al. The Lewy body variant of Alzheimer’s disease: a clinical and pathologic entity. Neurology 1990; 40: 1-8
54 Minoshima S, Foster NL, Sima AA et al. Alzheimer’s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001; 50: 358-365
55 Geser F, Wenning GK, Poewe W et al. How to diagnose dementia with Lewy bodies: state of the art. Mov Disord 2005; 20 (Suppl. 12) S11-S20
56 Walker RW, Walker Z. Dopamine transporter single photon emission computerized tomography in the diagnosis of dementia with Lewy bodies. Mov Disord 2009; 24 (Suppl. 02) S754-S759
57 Barber R, Ballard C, McKeith IG et al. MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology 2000; 54: 1304-1309
58 Donnemiller E, Heilmann J, Wenning GK et al. Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 1997; 24: 320-325
59 Klein JC, Eggers C, Kalbe E et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010; 74: 885-892
60 Kantarci K, Avula R, Senjem ML et al. Dementia with Lewy bodies and Alzheimer disease: neurodegenerative patterns characterized by DTI. Neurology 2010; 74: 1814-1821
61 Treglia G, Cason E. Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with lewy bodies and other dementias: a systematic review and a meta-analysis. J Neuroimaging 2012; 22: 111-117
62 Vernon AC, Ballard C, Modo M. Neuroimaging for Lewy body disease: is the in vivo molecular imaging of alpha-synuclein neuropathology required and feasible?. Brain Res Rev 2010; 65: 28-55
63 McKeith I, Del Ser T, Spano P et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031-2036
64 Thomas AJ, Burn DJ, Rowan EN et al. A comparison of the efficacy of donepezil in Parkinson’s disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 2005; 20: 938-944
65 Aarsland D, Ballard C, Walker Z et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009; 8: 613-618
66 Emre M, Tsolaki M, Bonuccelli U et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 969-977
67 Kurlan R, Cummings J, Raman R et al. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007; 68: 1356-1363
68 Rabey JM. Hallucinations and psychosis in Parkinson’s disease. Parkinsonism Relat Disord 2009; 15 (Suppl. 04) S105-S110
69 Nath U, Ben-Shlomo Y, Thomson RG et al. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology 2003; 60: 910-916
70 Nath U, Ben-Shlomo Y, Thomson RG et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain 2001; 124: 1438-1449
71 Bower JH, Maraganore DM, McDonnell SK et al. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999; 52: 1214-1220
72 Kasashima S, Oda Y. Cholinergic neuronal loss in the basal forebrain and mesopontine tegmentum of progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol 2003; 105: 117-124
73 Litvan I, Hauw JJ, Bartko JJ et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 1996; 55: 97-105
74 Hauw JJ, Daniel SE, Dickson D et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994; 44: 2015-2019
75 Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009; 8: 270-279
76 Williams DR, Lees AJ. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)?. Mov Disord 2010; 25: 357-362
77 Williams DR, de Silva R, Paviour DC et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain 2005; 128: 1247-1258
78 Williams DR, Holton JL, Strand K et al. Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord 2007; 22: 2235-2241
79 Canu E, Agosta F, Baglio F et al. Diffusion tensor magnetic resonance imaging tractography in progressive supranuclear palsy. Mov Disord 2011; 26: 1752-1755
80 Nomura T, Inoue Y, Takigawa H et al. Comparison of REM sleep behaviour disorder variables between patients with progressive supranuclear palsy and those with Parkinson’s disease. Parkinsonism Relat Disord 2012; 18: 394-396
81 Josephs KA, Petersen RC, Knopman DS et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006; 66: 41-48
82 Stamelou M, Knake S, Oertel WH et al. Magnetic resonance imaging in progressive supranuclear palsy. J Neurol 2011; 258: 549-558
83 Colosimo CFG, Berardelli A. Progressive supranuclear palsy. In: Colosimo CRD, Wenning GK. (eds.). Handbook of atypical parkinsonism. Cambridge: Cambridge University Press; 2011
84 Seppi K, Schocke MF, Esterhammer R et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003; 60: 922-927
85 Schulz JB, Skalej M, Wedekind D et al. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson’s syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1999; 45: 65-74
86 Gilman S, Koeppe RA, Nan B et al. Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes. Neurology 2010; 74: 1416-1423
87 Agosta F, Kostic VS, Galantucci S et al. The in vivo distribution of brain tissue loss in Richardson’s syndrome and PSP-parkinsonism: a VBM-DARTEL study. Eur J Neurosci 2010; 32: 640-647
88 Knake S, Belke M, Menzler K et al. In vivo demonstration of microstructural brain pathology in progressive supranuclear palsy: a DTI study using TBSS. Mov Disord 2010; 25: 1232-1238
89 Longoni G, Agosta F, Kostic VS et al. MRI measurements of brainstem structures in patients with Richardson’s syndrome, progressive supranuclear palsy-parkinsonism, and Parkinson’s disease. Mov Disord 2011; 26: 247-255
90 Hussl A, Mahlknecht P, Scherfler C et al. Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson’s disease and the Parkinson variant of multiple system atrophy. Mov Disord 2010; 25: 2444-2449
91 Kimura N, Hanaki S, Masuda T et al. Brain perfusion differences in parkinsonian disorders. Mov Disord 2011; 26: 2530-2537
92 Behnke S, Berg D, Naumann M et al. Differentiation of Parkinson’s disease and atypical parkinsonian syndromes by transcranial ultrasound. J Neurol Neurosurg Psychiatry 2005; 76: 423-425
93 Stamelou M, Christ H, Reuss A et al. Hypodipsia discriminates progressive supranuclear palsy from other parkinsonian syndromes. Mov Disord 2011; 26: 901-905
94 Aerts MB, Esselink RA, Abdo WF et al. CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 2012; 33: e431-e433
95 Borroni B, Gardoni F, Parnetti L et al. Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. Neurobiol Aging 2009; 30: 34-40
96 Litvan I, Blesa R, Clark K et al. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. Ann Neurol 1994; 36: 55-61
97 Litvan I. Diagnosis and management of progressive supranuclear palsy. Semin Neurol 2001; 21: 41-48
98 Stamelou M, de Silva R, Arias-Carrion O et al. Rational therapeutic approaches to progressive supranuclear palsy. Brain 2010; 133: 1578-1590
99 Stamelou M, Reuss A, Pilatus U et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord 2008; 23: 942-949
100 Ries V, Oertel WH, Hoglinger GU. Mitochondrial dysfunction as a therapeutic target in progressive supranuclear palsy. J Mol Neurosci 2011; 45: 684-689
101 Gozes I, Divinski I. NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Curr Alzheimer Res 2007; 4: 507-509
102 Sereno L, Coma M, Rodriguez M et al. A novel GSK-3beta inhibitor reduces Alzheimer’s pathology and rescues neuronal loss in vivo. Neurobiol Dis 2009; 35: 359-367
103 Dominguez JM, Fuertes A, Orozco L et al. Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem 2012; 287: 893-904
104 Litvan I. Progressive supranuclear palsy and corticobasal degeneration. Baillieres Clin Neurol 1997; 6: 167-185
105 Ling H, O’Sullivan SS, Holton JL et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 2010; 133: 2045-2057
106 Dickson DW, Bergeron C, Chin SS et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002; 61: 935-946
107 Murray R, Neumann M, Forman MS et al. Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology 2007; 68: 1274-1283
108 Arai T, Ikeda K, Akiyama H et al. Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration. Ann Neurol 2004; 55: 72-79
109 Whitwell JL, Jack Jr CR, Boeve BF et al. Imaging correlates of pathology in corticobasal syndrome. Neurology 2010; 75: 1879-1887
110 Hirano S, Shinotoh H, Shimada H et al. Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia. Brain 2010; 133: 2058-2068
111 Noble W, Planel E, Zehr C et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 2005; 102: 6990-6995
112 Lauterbach EC, Mendez MF. Psychopharmacological neuroprotection in neurodegenerative diseases, part III: criteria-based assessment: a report of the ANPA committee on research. J Neuropsychiatry Clin Neurosci 2011; 23: 242-260
113 Matsuoka Y, Jouroukhin Y, Gray AJ et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer’s disease. J Pharmacol Exp Ther 2008; 325: 146-153
114 Metzler M, Duerr S, Granata R et al. Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. J Neurol 2012;
115 Berardelli A, Wenning GK, Antonini A et al. EFNS/MDS-ES Recommendations for the Diagnosis of Parkinson’s Disease. Eur J Neurol im Druck
116 Duerr S, Wenning GK, Seppi K et al. Atypical Parkinson syndromes – recent advances in diagnosis and therapy. Fortschr Neurol Psychiatr 2012; 80: 492-500